Cryptic HBV, HCV and HEV infection in presumed nonA-E hepatitis

study there is no indication of why this may be, it may reflect the time taken to get test results back and then make a new appointment to see the patient. Our data does show that patients who have a biopsy result confirming cirrhosis with de-compensated liver disease take around 3 months longer to be initiated on treatment than those patients with minimal liver disease who can be stabilised and treated more effectively sooner. There is less differentiation when drug choices are considered. Patients prescribed tenofovir (22.6 months) are as likely to be initiated after roughly the same length of time as entecavir patients (25.2 months) and while patients being prescribed Lamivudine are likely to start treatment the soonest (19.0 months) this is related to other clinical reasons rather than linked to the drug choice. These data will provide a patient profile that will show the time expected to start drug treatment based on diagnostic conditions. With this information doctors will be able to set clear and achievable goals that will help their patient’s manage their condition better, and also prioritise patients and manage their caseload more efficiently based on a set of defined parameters.